网页
综合
更新时间 2026-11-15 01:42:38
Tech | AI, Chip & Semiconductor News | NewTimeSpace
On 13 Nov 2026, AB&B BIO-TECH-B (02627.HK) said China's CDE approved the IND for its tetanus vaccine candidate on 12 November.
On 13 Nov 2026, HENGRUI PHARMA (01276.HK) said it received clinical trial approvals for six drugs, including two ADCs, with applications accepted on 5 August.
On 13 Nov 2026, ZHAOKE OPHTH-B (06622.HK) said China's NMPA approved its cyclosporine ophthalmic gel for tear secretion in dry eye disease, dosed once nightly.
On 13 Nov 2026, HANSOH PHARMA (03692.HK) licensed AilsynBio's AI platform to find oral cyclic peptides, with payments reaching RMB 317 million plus royalties.
Agile Robots has closed a USD 500 million Series F at an USD 8.5 billion post-money valuation, led by SoftBank Group with NVIDIA and Hitachi among investors.
On 13 November 2026, Anthropic drew about six times the shares on offer in its IPO, seeking up to USD 64.4 billion plus USD 26 billion in a placement.
On 13 Nov 2026, SSY GROUP (02005.HK) said China's NMPA cleared its bevantolol hydrochloride as an API for marketed formulations, the third domestic approval.
On November 13, 2026, RoboSense (02498.HK) trended weaker. As of 15:39, it was quoted at HK$15.20, down 4.34%.
SMIC fell 0.49% to HKD 48.500 on 13 November 2026; Q3 revenue rose 33.9% to USD 3.19 billion and gross margin hit 29.9%, both above guidance.
UBTECH ROBOTICS fell 1.88% to HKD 73.100 on 13 November 2026 after signing a 100,000-unit humanoid robot target with Tianyi Telecom Terminal.
On 13 November 2026, Lingrui Zhixin said it had recently raised hundreds of millions of RMB in a Pre-A+ round led by Meituan; total funding nears RMB 1 billion.
On 13 November 2026, EVEREST MED (01952.HK) said China's NMPA approved a 100mg strength of XERAVA (eravacycline) for complicated intra-abdominal infections.
On 12 Nov 2026, DIAGENS-B (02526.HK) said its iMed-6.0 models led MMMU and MedBench tests, with Thoth first overall and Aegis second in health and medicine.
On 12 November 2026, Eli Radiopharma closed a Series A round of nearly RMB 400 million co-led by Huagai Capital and Bayland Capital; amount undisclosed.
On 12 Nov 2026, REMEGEN (09995.HK) amended its Vor Bio licence to add RC298, receiving about US$56m upfront and up to US$300m in development milestones.
Recently, Lingjie Aviation (Infini Aero, unlisted) closed a RMB 10 million-level angel round solely funded by Shanghai Huxiang Investment; terms undisclosed.
Printed By: NewTimeSpace Media Limited
Address: 19H Maxgrand Plaza, No.3 Tai Yau Street, San Po Kong, Kowloon,HK
Email: contact@newtimespace.com
On 13 Nov 2026, HENGRUI PHARMA (01276.HK) said it received clinical trial approvals for six drugs, including two ADCs, with applications accepted on 5 August.
On 13 Nov 2026, ZHAOKE OPHTH-B (06622.HK) said China's NMPA approved its cyclosporine ophthalmic gel for tear secretion in dry eye disease, dosed once nightly.
On 13 Nov 2026, HANSOH PHARMA (03692.HK) licensed AilsynBio's AI platform to find oral cyclic peptides, with payments reaching RMB 317 million plus royalties.
Agile Robots has closed a USD 500 million Series F at an USD 8.5 billion post-money valuation, led by SoftBank Group with NVIDIA and Hitachi among investors.
On 13 November 2026, Anthropic drew about six times the shares on offer in its IPO, seeking up to USD 64.4 billion plus USD 26 billion in a placement.
On 13 Nov 2026, SSY GROUP (02005.HK) said China's NMPA cleared its bevantolol hydrochloride as an API for marketed formulations, the third domestic approval.
On November 13, 2026, RoboSense (02498.HK) trended weaker. As of 15:39, it was quoted at HK$15.20, down 4.34%.
SMIC fell 0.49% to HKD 48.500 on 13 November 2026; Q3 revenue rose 33.9% to USD 3.19 billion and gross margin hit 29.9%, both above guidance.
UBTECH ROBOTICS fell 1.88% to HKD 73.100 on 13 November 2026 after signing a 100,000-unit humanoid robot target with Tianyi Telecom Terminal.
On 13 November 2026, Lingrui Zhixin said it had recently raised hundreds of millions of RMB in a Pre-A+ round led by Meituan; total funding nears RMB 1 billion.
On 13 November 2026, EVEREST MED (01952.HK) said China's NMPA approved a 100mg strength of XERAVA (eravacycline) for complicated intra-abdominal infections.
On 12 Nov 2026, DIAGENS-B (02526.HK) said its iMed-6.0 models led MMMU and MedBench tests, with Thoth first overall and Aegis second in health and medicine.
On 12 November 2026, Eli Radiopharma closed a Series A round of nearly RMB 400 million co-led by Huagai Capital and Bayland Capital; amount undisclosed.
On 12 Nov 2026, REMEGEN (09995.HK) amended its Vor Bio licence to add RC298, receiving about US$56m upfront and up to US$300m in development milestones.
Recently, Lingjie Aviation (Infini Aero, unlisted) closed a RMB 10 million-level angel round solely funded by Shanghai Huxiang Investment; terms undisclosed.
Printed By: NewTimeSpace Media Limited
Address: 19H Maxgrand Plaza, No.3 Tai Yau Street, San Po Kong, Kowloon,HK
Email: contact@newtimespace.com
本页为82搜索生成的网页快照，内容来自站内索引；演示数据的原文链接仅作示例。